Pharmaceutical Companies

Kenmare Bio will obtain worldwide development and commercialization rights to an experimental oral small molecule known as FHND5032, with the exception of Greater China, where Chia Tai Feng Hai will retain control.

Eli Lilly will obtain exclusive global rights to advance these programmed recombinases through preclinical studies, clinical development, and eventual commercialization.

The investment will enhance AstraZeneca’s existing manufacturing sites in Wuxi, Beijing, Qingdao, and Taizhou, which already serve patients in China and across 70 international markets.

Through this acquisition, Mirum gains worldwide rights to brelovitug, a monoclonal antibody that has advanced to Phase III clinical development.

The local production of dydrogesterone represents not only an important milestone for Mubadala Bio and Bioventure Healthcare but also a timely contribution to supporting women’s health throughout the country.

The approval specifically targets patients who have already undergone one prior trastuzumab-based treatment regimen.

Dr. Basson joins Variant Bio with more than 25 years of leadership experience spanning academic medicine, global pharmaceutical development, and biotechnology sectors.

The company plans to use the funding primarily to support a phase 2 clinical study evaluating Deraphan, its experimental treatment for agitation in patients with Alzheimer’s disease.

The plant is scheduled to begin operations by 2029 and will focus on producing cutting-edge treatments for metabolic conditions, particularly obesity medications.

The deal centers on ozureprubart, an anti-immunoglobulin E (IgE) antibody that could transform how patients manage life-threatening food allergies.